Mechlorethamine is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. It is available as gel for topical use. MedsAcross supplies Mechlorethamine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy. VALCHLOR is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.
Source: US FDA prescribing information
Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.
Source: US FDA prescribing information
For topical dermatological use only. Apply a thin film once daily to affected areas of the skin. Dosing and Dose Modification For Topical Dermatological Use Only Apply a thin film of VALCHLOR gel once daily to affected areas of the skin. Stop treatment with VALCHLOR for any grade of skin ulceration, blistering, or moderately-severe or severe dermatitis (i.e., marked skin redness with edema). Upon improvement, treatment with VALCHLOR can be restarted at a reduced frequency of once every 3 days. If reintroduction of treatment is tolerated for at least one week, the frequency of application can be increased to every other day for at least one week and then to once daily application if tolerated.
Source: US FDA prescribing information
The use of VALCHLOR is contraindicated in patients with known severe hypersensitivity to mechlorethamine. Hypersensitivity reactions, including anaphylaxis, have occurred with topical formulations of mechlorethamine. Severe hypersensitivity to mechlorethamine
Source: US FDA prescribing information
Mucosal or eye injury: VALCHLOR exposure to mucous membranes, especially of the eyes, can cause mucosal injury which may be severe. Eye injury may lead to blindness. Immediately irrigate for at least 15 minutes followed by immediate medical consultation. Secondary exposure to VALCHLOR: individuals other than the patient must avoid skin contact with VALCHLOR. Dermatitis: Monitor patients for redness, swelling, inflammation, itchiness, blisters, ulceration, and secondary skin infections. Stop treatment or reduce dose frequency. Non-melanoma skin cancer: Monitor patients during and after treatment. Embryo-fetal toxicity: May cause fetal harm. Flammable gel: VALCHLOR is an alcohol-based gel. Avoid fire, flame, and smoking until the gel has dried.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the prescribing information: Mucosal or eye injury Secondary exposure to VALCHLOR Dermatitis Non-melanoma skin cancer The most common adverse reactions (≥5%) are dermatitis, pruritus, bacterial skin infection, skin ulceration or blistering, and hyperpigmentation.
Source: US FDA prescribing information
No drug interaction studies have been performed with VALCHLOR. Systemic exposure has not been observed with topical administration of VALCHLOR, therefore, systemic drug interactions are not likely.
Source: US FDA prescribing information
Prior to dispensing, store in the freezer at -13°F to 5°F (-25°C to -15°C). Advise patients that refrigerated storage is required once dispensed.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Mechlorethamine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Valchlor 0.02% gelTopical Cold chain | Helsinn Therapeutics | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Mechlorethamine in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 1 presentations of Mechlorethamine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Mechlorethamine, including Valchlor.
Yes. The US FDA first approved Mechlorethamine on 15 March 1949, according to Drugs@FDA.
Yes. Mechlorethamine has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Mechlorethamine must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Mechlorethamine is classified under ATC code L01AA05 (Mechlorethamine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.